

Partnering for scientific leadership
Biotech unit partnering teams

Early-stage opportunities
(up to and including Phase I)



Innovative Medicines and Early Development (IMED)

Small molecules

Business Development Leadership	 Kumar Srinivasan Vice-President, Scientific Partnering & Alliances Kumar.Srinivasan@astrazeneca.com Waltham, USA	Oncology	 Maria Dahl Executive Director, Scientific Partnering & Alliances Maria.Dahl@astrazeneca.com Cambridge, UK
Cardiovascular, Renal & Metabolism	 Kay Brickmann Director, Scientific Partnering & Alliances Kay.Brickmann@astrazeneca.com Gothenburg, Sweden	Respiratory, Inflammation & Autoimmunity	 Bavani Shankar Senior Director, Scientific Partnering & Alliances Bavani.Shankar@astrazeneca.com Waltham, USA
External Collaborations	 Li Wang Director, Scientific Partnering & Alliances Li.Wang@astrazeneca.com Gothenburg, Sweden	Discovery Technologies; Neuroscience	 Iain Comley Director, Scientific Partnering & Alliances Iain.Comley@astrazeneca.com Cambridge, UK

MedImmune

Biologics

Business Development Leadership	 John Trainer Vice-President, Head of MedImmune Partnering & Strategy TrainerJ@medimmune.com Gaithersburg, USA	Oncology	 Jonathan Kiburz Director, MedImmune Partnering & Strategy KiburzJ@medimmune.com Gaithersburg, USA
Cardiovascular, Renal & Metabolism	 Eric Victory Vice-President, MedImmune Partnering & Strategy VictoryE@medimmune.com Gaithersburg, USA	Respiratory	 Gayatri Varma Director, MedImmune Partnering & Strategy VarmaG@medimmune.com Gaithersburg, USA
Oncology and Technology	 Lars Gredsted Associate Director, MedImmune Partnering & Strategy GredstedL@medimmune.com Cambridge, UK	Respiratory and Digital Health	 Laura Ferguson Associate Director, MedImmune Partnering & Strategy Laura.Ferguson@medimmune.com Cambridge, UK

For more information and full team contacts, please go to:
www.astrazeneca.com/partnering

Approval ID: Z4-14213 Date of preparation: December 2018 Date of expiry: December 2019

Partnering for scientific leadership



Mid- to late-stage and commercial
Small molecules and Biologics



Search & Evaluation

Oncology	 Chris Sheldon Head, Oncology Search & Evaluation Chris.Sheldon@astrazeneca.com Cambridge, UK	Cardiovascular, Renal & Metabolism	 Lori Kreamer Vice-President, Strategic Partnering & Early Asset Commercial Lori.Kreamer@astrazeneca.com Gaithersburg, USA
Respiratory	 Moustapha El-Amine Director, Global Search & Evaluation, Respiratory Moustapha.El-Amine@astrazeneca.com Gaithersburg, USA		

Business Development Operations

Business Development Leadership	 Shaun Grady Vice-President, Business Development Operations Shaun.Grady@astrazeneca.com Cambridge, UK	Alliance and Integration Management	 Steven Twait Vice-President, Alliance & Integration Management Steven.Twait@astrazeneca.com Cambridge, UK
Due Diligence	 John Easton Head of Business Operations John.Easton@astrazeneca.com Cambridge, UK	Sweden Business Development	 Ian Kirk Vice-President, Head of Business Development Sweden Ian.Kirk@astrazeneca.com Gothenburg, Sweden
United Kingdom Business Development and Precision Medicine and Genomics (PMG)	 Caroline Austin Vice-President, Head of Business Development UK and Head of PMG Business Development Caroline.Austin@astrazeneca.com Cambridge, UK	United States Business Development	 Mahmood Ladha Vice-President, Head of Business Development US Mahmood.Ladha2@astrazeneca.com Gaithersburg, USA

Corporate Development

Corporate Development	 Rodolphe Grepinet Vice-President, Corporate Development Rodolphe.Grepinet@astrazeneca.com Cambridge, UK	Corporate Development	 Tyrell Rivers Executive Director, Corporate Development RiversT@medimmune.com Gaithersburg, USA
----------------------------------	--	----------------------------------	--

For more information and full team contacts, please go to:
www.astrazeneca.com/partnering

Approval ID: Z4-14213 Date of preparation: December 2018 Date of expiry: December 2019